6505--Tacrolimus Capsules

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAC PHARMACEUTICALS (36E797)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36E79725R0057

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The solicitation titled "6505--Tacrolimus Capsules" (Procurement Identifier: 36E79725R0057) is issued by NAC Pharmaceuticals, a federal office operating under the organization key 500000036. This procurement seeks to secure a reliable supply of Tacrolimus Capsules, a critical pharmaceutical product classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505. The notice specifically addresses an extension of the due date and time for receipt of offers, providing additional time for interested vendors to prepare and submit their proposals. The primary objective of this procurement is to ensure the continued availability of Tacrolimus Capsules, which are essential for patient care within the federal healthcare system. Contractors are expected to demonstrate the capability to manufacture and deliver pharmaceutical-grade Tacrolimus Capsules in accordance with all applicable regulatory standards and quality requirements. The scope of work likely includes the consistent production, packaging, and timely delivery of these capsules to designated federal facilities, although specific quantities and delivery schedules are not detailed in the notice. NAC Pharmaceuticals, as the contracting entity, is responsible for overseeing the solicitation and subsequent contract administration. The primary point of contact for this opportunity is Richard Mahario, who can be reached via email at [email protected] for any inquiries related to the solicitation. This opportunity is classified as a solicitation and is currently marked as inactive, indicating that the response period has closed or the opportunity is no longer accepting submissions. The notice was originally posted on September 26, 2025, with a response deadline of October 9, 2025. Interested parties were directed to review the solicitation and its two attachments, available through the official SAM.gov listing (Opportunity ID: f2e477cca08f4b3189607326c7598e63), for comprehensive requirements and submission instructions. No specific set-aside requirements or special considerations are indicated in the provided information. Contractors evaluating this opportunity should ensure alignment with the pharmaceutical manufacturing scope and be prepared to meet federal standards for quality, reliability, and regulatory compliance throughout the contract lifecycle.